AG
KNSA icon

Algert Global’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Algert Global’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-35,847
Closed -$1.39M – 1240
2025
Q3 		$1.39M Sell
35,847
-196,340
-85% -$6.38M 0.02% 777
2025
Q2 		$6.42M Buy
232,187
+1,720
+0.7% +$43.8K 0.13% 249
2025
Q1 		$5.12M Buy
230,467
+94,653
+70% +$1.95M 0.13% 265
2024
Q4 		$2.69M Buy
135,814
+44,655
+49% +$1.02M 0.06% 506
2024
Q3 		$2.28M Buy
91,159
+72,556
+390% +$1.77M 0.06% 511
2024
Q2 		$347K Buy
18,603
+8,156
+78% +$153K 0.01% 1060
2024
Q1 		$206K Buy
+10,447
New +$204K 0.01% 972
2021
Q2 		– Sell
-12,140
Closed -$225K – 479
2021
Q1 		$225K Sell
12,140
-22,810
-65% -$467K 0.07% 360
2020
Q4 		$618K Hold
34,950
– – 0.18% 188
2020
Q3 		$535K Buy
34,950
+4,080
+13% +$76.6K 0.17% 179
2020
Q2 		$787K Buy
+30,870
New +$645K 0.27% 137
2019
Q1 		– Sell
-10,694
Closed -$300K – 353
2018
Q4 		$300K Buy
+10,694
New +$223K 0.08% 280

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Algert Global's KNSA Position: Q4 2025 in Review

Algert Global sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2025, closing a stake of 35,847 shares — an estimated $1.39M sold.

Algert Global first reported a position in KNSA in Q4 2018 and held it in 12 quarters. The position peaked at $6.42M in Q2 2025. 224 funds tracked by Wall St. Rank hold KNSA as of Q4 2025.

  • Algert Global reported no remaining Kiniksa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Algert Global sold 35,847 Kiniksa Pharmaceuticals shares in Q4 2025, an estimated $1.39M.
  • Algert Global first reported a position in Kiniksa Pharmaceuticals in Q4 2018 and held it in 12 quarters.
  • Algert Global's Kiniksa Pharmaceuticals position peaked at $6.42M in Q2 2025.
  • 224 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2025.

Based on Algert Global's 13F filing for Q4 2025, filed 17 Feb 2026.